[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"high-blood-sugar\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:high-blood-sugar":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100558766","phase-1-understanding-the-health-effect-of-a-bioactive-peptide-from-egg-a-pilot-study-100558766",false,"NCT06555393","Understanding the Health Effect of a Bioactive Peptide From Egg: A Pilot Study","A Preliminary Human Study on Bioavailability and Efficacy of Bioactive Peptide IRW in Egg White Hydrolysate","Inclusion Criteria:\n\nHealthy control group:\n\n* Men and women aged between 18 and 70 years living in Edmonton (or Edmonton area\u002Fdriving distance).\n* Normal weight (BMI below 25 kg\u002Fm2 or Asian population below 23 kg\u002Fm2 )\n* Waist circumference below the following ethnic specific cut offs: Canada \u002F USA: \\\u003C102 cm men and \\\u003C88 cm women; Europids, Middle-Eastern, Sub-Saharan African, and Mediterranean: \\\u003C94 cm men and \\\u003C80 cm women; Asians, Japanese, South and Central Americans: \\\u003C90 cm men and \\\u003C80 cm women\n* Fasting glucose \\\u003C5.6 mmol\u002FL\n* HbA1c \\\u003C5.6 %\n* Blood pressure \\\u003C130\u002F85 mmHg\n* Triglycerides \\\u003C1.7 mmol\u002FL\n* HDL-Cholesterol \\>1.03 mmol\u002FL men and \\>1.29 mmol\u002FL women\n* Body weight stable (within 3% fluctuation) for at least 6 months prior to the study\n* Individuals who have never smoke, have smoke less than 100 cigarettes in their life or who are long term quitter (quit smoking a year or more ago)\n\nIndividuals at risk of diabetes\u002Fhaving type 2 diabetes:\n\n* Men and women aged between 18 and 70 years living in Edmonton (or Edmonton area\u002Fdriving distance).\n* Overweight or obesity (BMI above 25 kg\u002Fm2 or Asian population above 23 kg\u002Fm2)\n* Waist circumference at or above the following ethnic specific cut offs: Canada \u002F USA: ≥ 102 cm men and ≥ 88 cm women; Europids, Middle-Eastern, Sub-Saharan African, and Mediterranean: ≥ 94 cm men and ≥ 80 cm women; Asians, Japanese, South and Central Americans: ≥ 90 cm men and ≥ 80 cm women\n* Fasting glucose ≥ 6.0 mmol\u002FL\n* HbA1c ≥ 6.0 %\n* Body weight stable (within 3% fluctuation) for at least 6 months prior to the study\n* Individuals who have never smoke, have smoke less than 100 cigarettes in their life or who are long term quitter (quit smoking a year or more ago)\n\nExclusion Criteria:\n\n* Individuals with a previous history of CVD, renal disorder, monogenic dyslipidemia, with endocrine disorders other than T2D\n* Individuals taking chronic anti-inflammatory drugs (including aspirin, antihistamines, and omega-3 supplements)\n* Pregnant\u002Flactating women\n* Individuals aged above 70 years\n* Smokers (current smokers: daily\u002Foccasional and those who have smoked more than 100 cigarettes in their life)\n* Individuals with specific nutritional restrictions (e.g. vegetarianism excluding eggs from their diet, vegan or with egg allergy) will be excluded\n* Individuals with poorly controlled (HbA1c \\>12.0%) diabetes or taking exogenous insulin will be excluded. Other anti-diabetic and lipid-lowering medications will be documented.",true,"ALL","18 Years","70 Years",{"count":21,"type":22},28,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","Bioactive peptides derived from food proteins show potential for improving human health. One of such promising peptides is namely IRW made from egg white hydrolysate and composed of three peptides. This is a feasibility study to assess the acute effect of IRW in egg white hydrolysate for the management of high sugar and blood pressure.\n\nParticipants at high risk of type 2 diabetes (T2D) or having T2D will undergo 4 consecutive treatments of 1 day each (randomly), during which they will consume a standardized breakfast with a smoothie containing different protein powders. Each treatment will be separated by a minimum of 1-week.\n\nParticipants in the healthy control group will undergo 1 treatment only (one day).",[28,29,30],"High Blood Sugar","High Blood Pressure","Overweight and Obesity",[32,33,34,35],"high blood pressure","high blood sugar","overweight","obesity","RECRUITING","2026-03-12",{"date":39,"type":40},"2026-03-13","ACTUAL",{"date":42,"type":40},"2026-02-25",{"date":44,"type":22},"2026-10",{"name":46,"class":47},"University of Alberta","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":48},"100495910","effect-of-ankascin-568-p-products-on-decreasing-hba1c-and-regulating-blood-glucose-100495910","NCT05737342","Effect of ANKASCIN 568-P Products on Decreasing HbA1c and Regulating Blood Glucose","Effect of ANKASCIN 568-P Products on Decreasing HbA1c and Regulating Blood Glucose- A Double-blind, Placebo-controlled Clinical Research","Inclusion Criteria:\n\n1. Men or non-pregnant women over 20 years old (women of childbearing age are not allowed to become pregnant or breastfeed during the study) adults who are sane and able to communicate.\n2. 18≦BMI≦35.\n3. Blood routine examination (CBC; Complete blood count): the mean corpuscular volume MCV should not be less than 70 fL.\n4. Blood glucose level measurement meets any of the following conditions:\n\n(1) The fasting blood sugar is between 100∼125 mg\u002FdL, and the doctor judges that there is no need to use hypoglycemic drugs for the time being.\n\n(2) Or the glycosylated hemoglobin is between 5.7∼6.4%, and the doctor judges that the use of hypoglycemic drugs is not needed for the time being.\n\n(3) Diabetic patients who have no willingness to take medicine and have not taken hypoglycemic drugs in the past month.\n\n5\\. Those without other serious diseases (cancer, heart failure, myocardial infarction, liver cirrhosis, moderate to severe liver and kidney dysfunction, stroke, etc.).\n\n6\\. Hypoglycemic drugs are not allowed to be used during the trial. If the condition changes and the use of hypoglycemic drugs is required, the trial must be withdrawn.\n\n7\\. During the test period, the daily routine and eating habits should be maintained without deliberately changing them.\n\nExclusion Criteria:\n\n1. Blood pressure: systolic blood pressure ≧ 200 mmHg or diastolic blood pressure ≧ 140 mmHg.\n2. Moderate or severe liver and kidney dysfunction (generally refers to serum aminopyruvate converting enzyme (SGPT) and serum glutamate phenylacetate transaminase (SGOT) are more than 3 times higher than the upper limit of normal value or have been diagnosed Liver cirrhosis, or glomerular filtration rate eGFR≦30 ml\u002Fmin\u002F1.73m2).\n3. Pregnant or lactating women.\n4. Diabetic patients taking hypoglycemic drugs or insulin injections.\n5. Those who take traditional Chinese medicine mainly red yeast rice.\n6. Have undergone surgery within one month.\n7. Combined with serious diseases such as heart, liver, kidney and hematopoietic system, mentally ill patients who do not meet the inclusion criteria, who do not eat the test samples according to the regulations, so that the efficacy cannot be judged or the incomplete data affect the judgment of efficacy or safety.","20 Years",{"count":58,"type":22},80,[60],"NA","This study is a randomized, double-blind, placebo-controlled, parallel-controlled trial (24 weeks in total), divided into three periods (screening, treatment, and discontinuation follow-up)",[28,63],"Metabolic Syndrome","2025-08-21",{"date":66,"type":40},"2025-08-28",{"date":68,"type":40},"2023-04-01",{"date":70,"type":22},"2025-10-31",{"name":72,"class":73},"SunWay Biotech Co., LTD.","INDUSTRY"]